5.0 μg/kg/hr to 30 μg/kg/hr of recombinant human activated protein C in combination with bacterial/permeability increasing (BPI) protein.

Cont A1

17. The method of Claim 16 wherein the BPI protein is recombinantly produced and is administered as a continuous infusion at about 50 μg/kg/hr to about 300 μg/kg/hr.

18. The method of Claim 16 wherein the BPI protein is recombinantly produced and is administered as a continuous infusion at about 100 μg/kg/hr to about 200 μg/kg/hr.

19. The method of any one of claims 16, 17, or 18 wherein the protein C plasma ranges in the human patient are from about 30 ng/ml to about 150 ng/ml.

20. The method of Claim 19 wherein the protein C plasma range in the human patient is 100 ng/ml.

21. The method of Claim 16 wherein about 0.1 mg/kg to about 10 mg/kg intravenous bolus of the BPI protein is administered followed by a continuous infusion of the BPI protein.

22. The method of Claim 19 wherein about 0.1 mg/kg to about 10 mg/kg intravenous bolus of BPI protein is administered followed by the continuous infusion.

23. The method of Claim 16 wherein the BPI protein is administered as an intermittent injection.

24. The method of Claim 16 wherein the human activated protein C infusion is administered for about 1 hour to about 240 hours.

25. The method of Claim 19 wherein the human activated protein C infusion is administered for about 1 hour to about 240 hours.

26. The method of Claim 17 wherein the BPI protein is administered for about 48 hours.

27. The method of Claim 18 wherein the BPI protein is administered for about 48 hours.

28. The method of Claim 24 wherein the BPI protein is administered for about 48 hours.